High plasma homocysteine is associated with the risk of coronary artery disease independent of methylenetetra-hydrofolate reductase 677C→T genotypes;Chinese source

Asia Pacific Journal of Clinical Nutrition

Volumn 17, Issue 2, 2008, Pages 330-338

  Lin, Ping Ting ^a   Huang, Men Chung ^b   Lee, Bor Jen ^c   Cheng, Chien Hsiung ^c   Tsai, Tsung Po ^d   Huang, Yi Chia ^e  

^a CHUNG CHOU INSTITUTE OF TECHNOLOGY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

B vitamins; Coronary artery disease; Gene polymorphism; Homocysteine; Methylenetetrahydrofolate reductase

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PYRIDOXINE; VITAMIN B COMPLEX;

ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; RISK FACTOR;

ALLELES; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 58149399868     PISSN: 09647058     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-81.
2. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol. 1998;9:533-9.
3. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000;72:324-32.
4. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58: 35-41.
5. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032-6.
6. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1998;43:414-21.
7. Kluijtmans LA, Kastelein JJP, Lindemans J, Boers GH J, Hell SG, Bruschke AVG et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573-7.
8. Amouzou EK, Chabi NW, Adjalla CE, Rodriguez-Gueant RM, Feillet F, Villaume C, Sanni A, Gueant JL. High prevalence of hyperhomocysteinemia related to folate deficiency and the 677C-->T mutation of the gene encoding methylenetetrahydrofolate reductase in coastal West Africa. Am J Clin Nutr. 2004;79:619-24.
9. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke. 2005;36:1581-7.
10. Brattström L, Wilcken DE, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98:2520-6.
11. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987; 422:43-52.
12. Bates CJ, Pentieva KD, Matthews N, Macdonald A. A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma. Clin Chim Acta. 1999;280:101-11.
13. Dominici R, Luraschi P, Franzini C. Measurement of C-reactive protein: two high sensitivity methods compared. J Clin Lab Anal. 2004;18:280-4.
14. Anderson JL, King GJ, Thomson J, Todd M, Bair TL, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increase risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997;30:1206-11.
15. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997;28:1739-43.
16. Jacques PF, Bostom AG, Williams RR, Ellison R C, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93:7-9.
17. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23.
18. 12 and homocysteine. Nutr Res. 2002;22:965-76.
19. Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE et al. EC Concerted Action Project: Homocysteine and Vascular Disease. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr. 2003;77:63-70.
20. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998;62:1258-60.
21. Klerk M, Verhoef P, Clarke P, Blom HJ, Kok FJ, Schouten EG et al. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288: 2023-31.
22. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94: 2410-6
23. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, Sung FC, Lee YT. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999;147:379-86.
24. Clark ZE, Bowen DJ, Whatley SD, Bellamy MF, Collins PW, McDowell IF. Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology. Clin Chem. 1998;44:2360-2.
25. Brown KS, Kluijtmans LA, Young IS, Murray L, McMaster D, Woodside JV et al. The 5,10-methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteine. Atherosclerosis. 2004;174:315-22.
26. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032-6.
27. 12 and homocysteine. Nutr Res. 2002;22:965-76.
28. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a multicenter case-control study in China. Stroke. 2003;34:2085-90.
29. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-27.
30. Kang SS, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest. 1986;77:1482-6.
31. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM Jr. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40:873-81.
32. Lee BJ, Lin PT, Liaw YP, Chang SJ, Cheng CH, Huang YC. Homocysteine and risk of coronary artery disease: Folate is the important determinant of plasma homocysteine concentration. Nutrition. 2003;19:577-83.
33. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am College Cardiol. 2003;41:2105-13.
34. Bǿnaa KH, Njǿlstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-88.
35. The Heart Outcomes Prevention Evaluation (HOPE) 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77.
36. Ubbink JB, Becker PJ, Vermaak WJH. Will an increased dietary folate intake reduce the incidence of cardiovascular disease? Nutr Rev. 1996;54:213-6.